Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized Trial of Immunotherapy With or Without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma

NCT05721755 is registered in ClinicalTrials.gov with ECOG-ACRIN Cancer Research Group as lead sponsor.

NCT NCT05721755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05721755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized Trial of Immunotherapy With or Without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma
Lead sponsor
ECOG-ACRIN Cancer Research Group
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 8, 2023
Completion date
March 31, 2030
Enrollment
290 (estimated)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage iv hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, metastatic head and neck squamous cell carcinoma, metastatic hypopharyngeal squamous cell carcinoma, metastatic laryngeal squamous cell carcinoma, metastatic oral cavity squamous cell carcinoma, metastatic oropharyngeal squamous cell carcinoma, stage iv cutaneous squamous cell carcinoma of the head and neck ajcc v8, stage iv hypopharyngeal carcinoma ajcc v8, stage iv laryngeal cancer ajcc v8, stage iv lip and oral cavity cancer ajcc v8, stage iv oropharyngeal (p16-negative) carcinoma ajcc v8